UK Drug Safety Update · July 07, 2025

Abrysvo (Pfizer RSV vaccine) and Arexvy (GSK RSV vaccine): alert to small risk of Guillain-Barré syndrome in older adults

Original title: Abrysvo▼ (Pfizer RSV vaccine) and Arexvy▼ (GSK RSV vaccine): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults

Small increased risk of Guillain-Barré syndrome identified following RSV vaccination in adults aged 60 years and older.

High impact Pharmaceuticals Public Health UK pharmacovigilancevaccination

There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthca…

Read the official source ↗

Published by UK Drug Safety Update. HealthSignal links to the original document; the summary above is extracted from the source text.